Key Takeaways Tempus AI partnered with NYU Langone Health to improve genetic diagnostics and data-driven cancer care.TEM's collaboration covers biomarker discovery, AI tools and real-world data analysis to guide treatment. TEM is expanding genomic testing access with Northwestern Medicine for early and advanced cancer patients. Tempus AI (TEM) recently started working with leading academic medical centers to broaden access to advanced genomic testing and data-driven cancer care. In line with this, Tempus an ...

Group 1 - Tempus AI Inc. (NASDAQ:TEM) experienced a significant stock increase of 15% to $76.33, driven by strong demand for its services and $1.1 billion in sealed contracts, with a revenue retention rate of approximately 126% last year [1][4] - The company secured data agreements with 70 customers in the past year, including major pharmaceutical firms such as AstraZeneca, GlaxoSmithKline, and Pfizer, as well as various biotechnology companies [2] - The Chief Finance Officer of Tempus AI highlighted that 2025 was a record year for the company's Data and applications business in terms of revenue and total contract value (TCV) [3] Group 2 - The company expressed confidence in its growth trajectory, stating that its engagement with life sciences companies has strengthened, positioning its data business for continued growth into 2026 and beyond [4] - Tempus AI plans to announce its finalized financial and operating performance for 2025 during an earnings call scheduled for February 2026 [4]

PresentationAll right. Great. Welcome, everybody. I'm Casey Woodring from the Life Science Tools and Diagnostics team here at JPMorgan. Welcome to our conference. Pleased to be joined by Tempus AI, CEO, Eric Lefkofsky. We'll go through the corporate presentation, then leave time for the Q&A afterwards. Eric, all yours.Eric LefkofskyCo-Founder, CEO, President & Chairman Thank you. Welcome. There's seats up here -- for people in the back, but by all means, feel free to walk up. So I'll try to give you a littl ...

Tempus AI (NasdaqGS:TEM) FY Conference January 12, 2026 04:30 PM ET Company ParticipantsEric Lefkofsky - Founder and CEOConference Call ParticipantsCasey Woodring - AnalystCasey WoodringAll right, great. Welcome, everybody. I'm Casey Woodring from the Life Science Tools and Diagnostics team here at J.P. Morgan. Welcome to our conference. Pleased to be joined by Tempus AI CEO Eric Lefkofsky. We'll go through the corporate presentation, then leave time for the Q&A afterwards. Eric, all yours.Eric LefkofskyTha ...

Company Overview - Tempus aims to unlock precision medicine through AI-enabled diagnostics[6] - The company's platform connects to over 5,000 providers across the US[10] - Tempus leverages a large proprietary healthcare dataset of over 45 million patient records[13] Diagnostics Business - The Diagnostics business delivered approximately 800,000 clinical tests in 2025[30] - The Diagnostics business experienced a unit growth rate of approximately 28% in Q4 2025[30] - Oncology ASP is expected to rise by over $500 in the next several years due to reimbursement tailwinds[31] Data & Applications Business - Data and Applications revenue reached approximately $316 million in 2025, representing approximately 31% growth[38] - The Data & Applications business has signed over $2 billion in contracts to date[38] - The Total Remaining Contract Value (TCV) for Data & Applications is over $1.1 billion as of year-end 2025[39] - The Data Licensing Retention rate is approximately 126% as of year-end 2025[39] Financial Outlook - The company anticipates revenue of approximately $1.27 billion for 2025, reflecting approximately 83% year-over-year growth[63] - The company projects revenue growth of approximately 25% year-over-year in 2026, reaching approximately $1.59 billion[65]

Key Takeaways TEM stock gained 105% in a year as Genomics and Data results exceeded expectations for 2025. Tempus earned multiple FDA 510(k) clearances, expanding its AI-based diagnostics and imaging portfolio. TEM delivered positive adjusted EBITDA, though GAAP losses continue due to compensation and amortization. Tempus AI (TEM) stock has delivered a remarkable 105% gain over the past year, driven by strong performance across both its Genomics and Data segments, surpassing initial expectations for 2025. A ...

Tempus AI stock remains in a bear market after crashing by 36% from its highest point in September last year. It has slumped to $66, with its market capitalization slumping from $17.8 billion in Octob... ...

数据与应用业务营收约1亿美元，同比增长约25%(若剔除2024年第四季度阿斯利康认股权证的影响，则 洞察业务增长约68%)。 Tempus创始人兼首席执行官Eric Lefkofsky表示："2025年对Tempus来说是卓越的一年，我们两条产品线 的表现均超出了年初预期。在诊断业务中，我们的基因组学(肿瘤)产品检测量同比增长已连续三个季度 加速，达到了多年来最高的单位增长率。 我们的数据与应用业务表现更为强劲，第四季度营收创下约1亿美元的纪录，全年增长约31%，其中数 据授权业务增长约38%。我们以异常强劲的态势进入2026年，两大主营业务增长均在加速，并释放出我 们平台固有的财务杠杆效应。随着AI成为我们所有产品的催化剂，我们对2026年充满期待。" 致力于推动人工智能应用于精准医疗的领先技术公司Tempus AI(TEM.US)公布了截至2025年12月31日的 第四季度及全年初步未经审计的业绩摘要。报告称，其2025年营收约为12.7亿美元，实现同比增长约 83%(其中有机增长约30%，不含Ambry Genetics业务贡献)。截至发稿，该股盘前涨12%。 数据显示，该公司2025年度诊断业务营收约 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 11, 2026 Tempus AI, Inc. (Exact name of Registrant as Specified in Its Charter) (State or Other Jurisdiction of Incorporation) 600 West Chicago Avenue Suite 510 Chicago, Illinois 60654 (Address of Principal Executive Offices) (Zip Code) (Commission File Number) Nevada 001-42130 47-49033 ...

U.S. stock futures declined on Monday after a positive close on Friday. Futures of major benchmark indices were trading lower.Tensions flared up at the Federal Reserve after the Chair Jerome Powell said on Sunday that the Department of Justice had threatened the central bank with "criminal indictment" over his testimony before Congress, relating to its building renovation costs. This marks a major escalation in tensions between President Donald Trump and the central bank. On Friday, nonfarm payrolls increas ...